Posts by Muana Minkoué
Addex and Perceptive launch Neurosterix with USD 63 Million investment
Geneva-based Addex Therapeutics and funds affiliated with Perceptive Advisors, an investment management firm focused on the life sciences sector, today announced the launch of Neurosterix to accelerate development of allosteric modulator therapeutics for neurological disorders. With initial funding of $63 million from Perceptive Xontogeny Venture Fund II, Neurosterix will acquire a portfolio of…
Read MoreVolumina Medical secures USD 21 Million Funding
Volumina Medical, a clinical stage MedTech company developing novel biomaterials for dermatology and plastic surgery, announces the successful closing of their Series A round by existing and new investors. It will enable Volumina Medical to confidently advance its clinical program with its lead product AdipearlTM, and ultimately achieve market approval in key international markets. …
Read MoreVenture Leaders Biotech unveils its 2024 cohort for the Boston roadshow
The Swiss National Startup Team has selected its 10 startups for the Venture Leaders Biotech 2024. The entrepreneurs will meet international investors and industry leaders during their roadshow and access industry-specific expertise to grow their ventures. Selected from over 70 applications by a jury of investors and biotech experts, the ten startups will…
Read MoreUNIGE discovers why infections persist after cystic fibrosis treatment
A UNIGE team discovered that treatment for cystic fibrosis does not eliminate the docking stations of bacteria responsible for respiratory infections. Cystic fibrosis is a genetic disease that causes serious and sometimes fatal respiratory and digestive disorders. A new treatment, available since 2020, improves lung function and quality of life. However, it does…
Read MoreOrio Therapeutics Secures CHF 500’000 Pre-Seed Funding
Orio Therapeutics, a biotechnology company at the forefront of protein engineering for regenerative medicine, announced the successful closure of a CHF 500’000 pre-seed funding round. This investment, secured from angel investors, will propel the company’s ambitious goal of revolutionising treatment approaches for patients suffering from debilitating conditions. Orio Therapeutics will utilise the funding…
Read MoreThe crucial role of trademark and patent registration for startups
With more than 50 years’ experience, Katzarov advise companies and entrepreneurs on all matters related to intellectual property (IP). Thanks to their expertise, they highlight the key insights of the latest “Patents, Trademarks and Startup Finance” study for startups. Startups have emerged as key drivers of economic growth, innovation, and job creation in…
Read MoreAnna Fontcuberta i Morral to be the next EPFL president
Professor Fontcuberta i Morral will be the first woman to lead a Swiss Federal Institute of Technology since they were founded in 1855. She will take over as EPFL president on January 1 2025. Her appointment marks another achievement in an outstanding career. A physicist and materials scientist, Professor Fontcuberta i Morral joined…
Read MoreEPFL is locating single neurons that monitor and regulate the heart and lungs
EPFL neuroscientists have located single neurons in a deep structure of the brain that regulates the heart and the lungs, a first detection in humans. The results shed light on how the brain-body system self-regulates both vital bio-rhythms. EPFL neuroscientists, in a collaboration with surgeons and neuroscientists at West Virginia University Rockefeller Neuroscience…
Read MoreThe HES-SO Valais-Wallis Institute of Informatics will lead a European project
The Institute of Informatic’s eHealth research cluster has been awarded scientific coordination of the European Hereditary project. The project aims to revolutionise disease detection, plan treatment response and explore medical knowledge of neurodegenerative diseases such as Parkinson and Alzheimer. Hereditary innovates by integrating heterogeneous semantic data to analyse the interactions between the brain…
Read MoreSpineart successfully raised a CHF20 Million convertible financing
Spineart secures more than CHF 20 Million in convertible financing following completion of BAGUERA® C IDE studies enrolment. The funding comes on the heels of the completion of enrolment in the two BAGUERA® C IDE studies, underlining Spineart’s commitment to advancing spinal surgery through large-scale investments in research and development. More than CHF…
Read More